The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention

Table 5

A classification of non-cancer patients already in treatment with MRONJ-related drugs.

Risk assessment of MRONJ in non-cancer patients
Category A	Category B
(i) Patients eligible and not yet treated with ONJ-related medication; (ii) Patients exposed to ONJ-related medication for less than 3 years, in absence of other systemic risk factors	(i) Patients exposed to ONJ-related medication for more than 3 years; (ii) Patients exposed to ONJ-related medication for less than 3 years and in presence of other systemic risk factors; (iii) Patients assuming BPs by

date, there exists no data to distinguish groups of patients in treatment with zoledronate intravenous (annual medication intake) at greater or lesser risk of developing MRONJ.